摘要
[摘要]目的探讨白芍总苷胶囊对慢性肾脏病（CKD）患者肾脏保护的可能作用机制。方法将56例CKD2—3期患者随机分对照组和治疗组各28例。两组患者均给予西医基础治疗，对照组在基础治疗同时口服潘生丁片，每次50mg，每日3次；治疗组在基础治疗同时1：7服白芍总苷胶囊，每次0．6g，每日3次，两组疗程均为8周。于治疗前后观察两组患者24h尿蛋白定量、血清白蛋白、血肌酐、肌酐清除率及白细胞介素-6（IL-6）、转化生长因子-p1（TGF-β1）的变化。结果与治疗前比较，对照组IL-6显著下降（P〈0．05），治疗组血肌酐、肌酐清除率、IL．6、TGF-β1均显著改善（P〈0．01）；治疗组治疗后较对照组血肌酐、肌酐清除率、IL-6、TGF-β1均显著改善（P〈0．05或P〈0．01）。经Spearman相关分析，TGF-β1下降与IL-6呈正相关，相关系数r=0．858（P〈0．01）。结论白芍总苷可下调CKD患者IL．6水平及抑制TGF-β1表达，可能是延缓CKD进程的机制之一。
ABSTRACT Objective To research the possible protection mechanism of total glucosides of paeony （TGP） in patients with chronic kidney disease （CKD）. Methods Totally 56 patients with stage I] to III CKD were randomized into the treatment group and control group, with 28 in each. Both groups were given basic treatment. The control group was added with 50mg dipyridamole tablets three times daily, while the treatment group was added with O. 6 g TGP capsules three times daily. The treatment lasted for 8 weeks. The changes of 24 h urine total protein （24 h-UTP） , serum albumin （ Alb ）, serum creatinine （Scr） , creatinine clearance （ Ccr）, interleukin-6 （ IL-6 ） and transforming growth factor-J31 （TGF-I31） were observed before and after treatment. Results The level of IL-6 was significantly decreased in the control group after treatment （P 〈0. 05 ）. The Scr, Ccr, IL-6 and TGF-131 were signifi- cantly improved in the treatment group after treatment （P 〈 0.01 ）. Comparing with the control group, Scr, Ccr, IL- 6 and TGF-β1 were significantly improved in the treatment group after treatment （ P 〈 0. 05 or P 〈 0. 01 ）. The Spearman correlation analysis showed that TGF-β1 was positively correlated with IL-6 （ r = 0. 858, P 〈 0. 01 ）. Conclusion TGP can delay the process of CKD possibly by down-regulating the level of IL-6 and inhibiting the ex- pression of TGF-β1.
出处
《中医杂志》
CSCD
北大核心
2014年第9期772-774,共3页
Journal of Traditional Chinese Medicine
基金
广西壮族自治区教育厅科研资助项目(200810LX056)
广西科学基金资助项目(桂科自0542102)
关键词
慢性肾脏病
白芍总苷
白细胞介素-6
转化生长因子-Β1
chronic kidney disease
total glucosides of paeony
interleukin-6
transforming growth factor-βl
